18889881171
Kalkine 0
countryflagUS

Arcellx Inc

Healthcare US ACLX

66.305USD
-0.205(0.31%)

Last update at 2025-06-13T16:47:00Z

Day Range

64.9066.45
LowHigh

52 Week Range

30.7475.10
LowHigh

Fundamentals

  • Previous Close 66.51
  • Market Cap2744.68M
  • Volume150873
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-72.79900M
  • Revenue TTM131.66M
  • Revenue Per Share TTM2.66
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -188.67900M -64.96900M -32.09500M -17.97200M -
Minority interest - - - - -
Net income -186.09900M -63.92800M -32.09500M -17.97200M -
Selling general administrative 41.70M 18.14M 7.04M 2.21M -
Selling and marketing expenses - - - - -
Gross profit - - - - -
Reconciled depreciation 1.32M 1.04M 0.63M 0.33M -
Ebit -191.25900M -66.05900M -32.09600M -17.97400M -8.30900M
Ebitda -186.95900M -65.01800M -31.46700M -17.64800M -
Depreciation and amortization 4.30M 1.04M 0.63M 0.33M -
Non operating income net other - - - - -
Operating income -191.25900M -65.01800M -32.09600M -17.97400M -
Other operating expenses 191.26M 65.02M 32.10M 17.97M -
Interest expense 1.72M 0.05M 0.00000M 0.00000M 0.00000M
Tax provision - - - - -
Interest income 4.30M - - - -
Net interest income 2.58M - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.58000M -1.04100M -0.00100M -0.00200M -
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M -
Total operating expenses 191.26M 65.02M 32.10M 17.97M -
Cost of revenue - - - - -
Total other income expense net 2.58M 0.05M 0.00100M 0.00200M -
Discontinued operations - - - - -
Net income from continuing ops -188.67900M -64.96900M -32.09500M -17.97200M -
Net income applicable to common shares -188.67900M -64.96900M -32.09500M -17.97200M -8.30800M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 825.13M 313.82M 128.78M 57.69M 43.59M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 14.35M 12.03M 2.05M 1.21M 0.62M
Total liab 339.75M 108.86M 250.30M 121.41M 76.33M
Total stockholder equity 485.38M 204.95M -121.51500M -63.72000M -32.73800M
Deferred long term liab - 4.56M 3.17M 1.76M -
Other current liab 18.30M 11.68M 13.51M 4.77M 1.29M
Common stock 0.05M 0.04M 0.00100M 0.00100M 0.00100M
Capital stock 0.05M 0.04M 0.00100M 0.00100M 0.00100M
Retained earnings -389.48000M -318.79000M -130.11100M -65.14200M -33.04700M
Other liab - - 1.90M 1.88M 1.83M
Good will - - - - -
Other assets 11.77M 7.06M 5.66M 3.44M 1.19M
Cash 394.58M 64.18M 104.62M 46.60M 34.58M
Cash and equivalents - - - - -
Total current liabilities 118.24M 56.69M 14.85M 5.27M 3.04M
Current deferred revenue 50.53M - - - -
Net debt -296.95800M 23.95M -104.61700M -46.59600M -34.57800M
Short term debt 46.78M 35.96M - - -
Short long term debt - - - - -
Short long term debt total 97.62M 88.13M - - -
Other stockholder equity 874.26M 523.92M -20.27900M 1.42M 0.31M
Property plant equipment - - 10.32M 4.90M 4.33M
Total current assets 716.36M 266.86M 112.81M 49.36M 38.07M
Long term investments 27.17M - - - -
Net tangible assets - 204.95M -121.51500M -63.72000M -32.73800M
Short term investments 307.43M 190.66M 73.78M - -
Net receivables - - - - -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 2.62M 9.05M 1.33M 0.50M 1.75M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.55M -0.22100M -0.02000M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other -96.99500M 7.06M 5.66M 3.44M 1.19M
Deferred long term asset charges - - - - -
Non current assets total 97.00M 46.95M 15.97M 8.34M 5.52M
Capital lease obligations 97.62M 88.13M - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -117.67400M -74.19300M -0.88800M -3.83200M -74.19300M
Change to liabilities 7.42M 0.97M -1.33300M 0.69M 0.86M
Total cashflows from investing activities -117.67400M -79.97600M -0.88800M -3.83200M -0.47900M
Net borrowings - -0.38700M -0.38700M -0.38700M -0.38700M
Total cash from financing activities 252.62M 118.45M 41.66M 42.65M 12.48M
Change to operating activities -2.96700M 1.75M 3.09M -1.95000M 0.43M
Net income -188.67900M -64.96900M -32.09500M -17.97200M -8.30800M
Change in cash 35.65M -15.76300M 12.11M 20.05M 5.14M
Begin period cash flow 31.03M 46.80M 34.69M 14.64M -
End period cash flow 66.68M 31.03M 46.80M 34.69M 14.64M
Total cash from operating activities -99.30300M -54.23800M -28.66200M -18.77200M -6.86100M
Issuance of capital stock 259.83M 119.12M 42.80M 42.57M -
Depreciation 1.32M 1.04M 0.63M 0.33M 0.09M
Other cashflows from investing activities - - - - -
Dividends paid - 119.12M - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock 0.00000M -0.02400M - - -
Other cashflows from financing activities 2.47M 118.86M 41.66M -3.83200M -1.18500M
Change to netincome 83.60M 6.97M 1.05M 0.14M 0.07M
Capital expenditures 2.28M 5.78M 0.89M 3.83M 0.48M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 4.45M 2.72M 1.75M -1.26200M -
Stock based compensation 21.54M 6.75M 1.05M 0.14M -
Other non cash items 62.06M 0.21M -7.30300M - -
Free cash flow -101.58000M -60.02100M -29.55000M -22.60400M -

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACLX
Arcellx Inc		 -0.205 0.31% 66.31 - - 28.05 6.38 22.57 -38.8211
NVO
Novo Nordisk A/S		 -0.56 0.69% 80.49 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.41 0.51% 80.59 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -1.29 0.28% 458.77 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 2.82 0.54% 524.66 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Arcellx Inc

800 Bridge Parkway, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Mr. Rami Elghandour Chairman, CEO & Pres 1979
Mr. Neeraj P. Teotia Chief Commercial Officer 1975
Dr. Christopher R. Heery M.D. Chief Medical Officer 1980
Ms. Michelle Lim Gilson Chief Financial Officer 1992
Mr. Michael Dombeck M.B.A. Chief Operating Officer NA
Mr. Narinderjeet Singh M.S. Chief Technical Officer 1972
Mr. David Tice Ph.D. Chief Scientific Officer 1971
Ms. Myesha Lacy VP of Investor Relations NA
Ms. Maryam Abdul-Kareem J.D., M.S. Gen. Counsel NA
Ms. Kate Aiken Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.